Biotechnology and Pharmaceuticals

September 30, 2021

Buy ($175)

Companies covered: Autolus Therapeutics PLC (NASDAQ:AUTL), Chinook Therapeutics Inc. (NASDAQ:KDNY), Gilead Sciences, Inc. (NASDAQ:GILD), Novartis AG (NYSE:NVS), Bristol-Myers Squibb Company (NYSE:BMY), Incyte Corporation (NASDAQ:INCY), Zoetis Inc. (NYSE:ZTS), IDEXX Laboratories, Inc. (NASDAQ:IDXX), Covetrus (NASDAQ:CVET), Henry Schein, Inc. (NASDAQ:HSIC), Chewy (NYSE:CHWY), Amazon.com, Inc. (NASDAQ:AMZN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Bausch Health Companies (NYSE:BHC), AbbVie Inc. (NYSE:ABBV), Moderna (NASDAQ:MRNA), BioNTech SE (ADR) (NASDAQ:BNTX), Biogen Inc. (NASDAQ:BIIB), UCB Unsponsored Belgium ADR (OTCMKTS:UCBJY), Landos Biopharma Inc. (NASDAQ:LABP), CohBar Inc. (NASDAQ:CWBR), Omeros Corporation (NASDAQ:OMER), STERIS Corporation (NYSE:STE), Cutera, Inc. (NASDAQ:CUTR), Establishment Labs Holdings Inc. (NASDAQ:ESTA), Glaukos Corp (NYSE:GKOS), Cooper Companies, Inc. (The) (NYSE:COO), SmileDirectClub (NASDAQ:SDC), Vericel Corporation (NASDAQ:VCEL), Baxter International Inc. (NYSE:BAX), Hill-Rom Holdings Inc (NYSE:HRC), Soliton Inc. (NASDAQ:SOLY), EssilorLuxottica SA (OTCMKTS:ESLOF), Pulse BioSciences Inc. (NASDAQ:PLSE), Passage Bio Inc. (NASDAQ:PASG), Taysha Gene Therapies Inc. (NASDAQ:TSHA), Iovance Biotherapeutics Inc. (NASDAQ:IOVA), Homology Medicines Inc. (NASDAQ:FIXX), Regenxbio Inc. (NASDAQ:RGNX), Tenaya Therapeutics Inc. (NASDAQ:TNYA), Astellas Pharma Inc. (OTCMKTS:ALPMF), LogicBio Therapeutics Inc. (NASDAQ:LOGC), Intellia Therapeutics Inc. (NASDAQ:NTLA), Pfizer, Inc. (NYSE:PFE), Allogene Therapeutics (NASDAQ:ALLO), Cellectis S.A. (NASDAQ:CLLS), CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), Rocket Pharmaceuticals (NASDAQ:RCKT), Krystal Biotech (NASDAQ:KRYS), uniQure N.V. (NASDAQ:QURE), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), GBS Inc. (NASDAQ:GBS), Inhibikase Therapeutics, Inc. (NASDAQ:IKT), Mesoblast Limited (NASDAQ:MESO), USA Equities Corp. (OTCMKTS:USAQ)

Medical Devices

June 10, 2021

Buy ($175)

Companies covered: Danaher Corporation (NYSE:DHR), Avantor (NYSE:AVTR), Agilent Technologies, Inc. (NYSE:A), EXACT Sciences Corporation (NASDAQ:EXAS), PerkinElmer, Inc. (NYSE:PKI), Thermo Fisher Scientific Inc (NYSE:TMO), Abbott Laboratories (NYSE:ABT), Hologic, Inc. (NASDAQ:HOLX), Novocure Ltd. (NASDAQ:NVCR), Illumina, Inc. (NASDAQ:ILMN), Johnson & Johnson (NYSE:JNJ), Medtronic, Inc. (NYSE:MDT), Edwards Lifesciences Corporation (NYSE:EW), Quidel Corporation (NASDAQ:QDEL), Intuitive Surgical, Inc. (NASDAQ:ISRG), Ortho Clinical Diagnostics Holdings PLC (NASDAQ:OCDX), PPD Inc. (NASDAQ:PPD), DexCom, Inc. (NASDAQ:DXCM), Zimmer Biomet Holdings Inc. (NYSE:ZBH), Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Stryker Corporation (NYSE:SYK), Glaukos Corp (NYSE:GKOS), Cooper Companies, Inc. (The) (NYSE:COO), Insulet Corporation (NASDAQ:PODD), Inogen, Inc (NASDAQ:INGN), Sientra, Inc. (NASDAQ:SIEN), Boston Scientific Corporation (NYSE:BSX), Koninklijke Philips N.V. (NYSE:PHG), Irhythm Technologies Inc. (NASDAQ:IRTC), Soliton Inc. (NASDAQ:SOLY), Neuronetics Inc. (NASDAQ:STIM), Eargo Inc. (NASDAQ:EAR), electroCore, Inc. (NASDAQ:ECOR), IsoRay, Inc. (NYSEAMERICAN:ISR), ReWalk Robotics Ltd (NASDAQ:RWLK), Sensus Healthcare (NASDAQ:SRTS)

Biotechnology and Pharmaceuticals

March 18, 2021

Buy ($175)

Companies covered: Arcturus Therapeutics Ltd. (NASDAQ:ARCT), Vaxart (NASDAQ:VXRT), Veru (NASDAQ:VERU), Moderna (NASDAQ:MRNA), Pfizer, Inc. (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Atreca (NASDAQ:BCEL), BioCardia Inc. (NASDAQ:BCDA), Forte Biosciences Inc. (NASDAQ:FBRX), Caladrius Biosciences Inc. (NASDAQ:CLBS), Medicenna Therapeutics Corp. (NASDAQ:MDNA), SpringWorks Therapeutics (NASDAQ:SWTX), bluebird bio, Inc. (NASDAQ:BLUE), AVROBIO (NASDAQ:AVRO), Blueprint Medicines Corp. (NASDAQ:BPMC), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Argenx SE (ADR) (NASDAQ:ARGX), Magenta Therapeutics Inc. (NASDAQ:MGTA), Scholar Rock Holding Corp. (NASDAQ:SRRK), Orchard Therapeutics PLC – ADR (NASDAQ:ORTX), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH), Ortho Regenerative Technologies Inc. (OTCMKTS:ORTIF), Lantern Pharma Inc. (NASDAQ:LTRN), Kintara Therapeutics Inc. (NASDAQ:KTRA), DarioHealth Corp. (NASDAQ:DRIO), AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ:ANPC), BiOasis Technologies Inc. (OTCMKTS:BIOAF), Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX), electroCore, Inc. (NASDAQ:ECOR), MiMedx Group, Inc (NASDAQ:MDXG), Heat Biologics, Inc. (NASDAQ:HTBX), Achieve Life Sciences (NASDAQ:ACHV), Zoom Video Communications (NASDAQ:ZM), Amazon.com, Inc. (NASDAQ:AMZN), Walt Disney Company (The) (NYSE:DIS), Netflix, Inc. (NASDAQ:NFLX), Amarin Corporation PLC (NASDAQ:AMRN), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Durect Corporation (NASDAQ:DRRX), Cancer Genetics, Inc. (NASDAQ:CGIX), Quick-Med Technologies Inc. (OTCMKTS:QMDT), VolitionRX Limited (NYSEAMERICAN:VNRX), NovelStem International Corp. (OTCMKTS:NSTM)

Biotechnology and Pharmaceuticals

September 21, 2020

Buy ($175)

Companies covered: Moderna (NASDAQ:MRNA), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Novavax, Inc. (NASDAQ:NVAX), Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), Vir Biotechnology (NASDAQ:VIR), Emergent Biosolutions, Inc. (NYSE:EBS), Oxford BioMedica plc (OTCMKTS:OXBDF), Luminex Corporation (NASDAQ:LMNX), Quidel Corporation (NASDAQ:QDEL), GlaxoSmithKline PLC (NYSE:GSK), AstraZeneca PLC (NASDAQ:AZN), Sanofi (NYSE:SNY), Pfizer, Inc. (NYSE:PFE), BioNTech SE (ADR) (NASDAQ:BNTX), Patterson Companies, Inc. (NASDAQ:PDCO), Henry Schein, Inc. (NASDAQ:HSIC), Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), Johnson & Johnson (NYSE:JNJ), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Endo International plc (NASDAQ:ENDP), Eli Lilly and Company (NYSE:LLY), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Zoetis Inc. (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Merck & Company, Inc. (NYSE:MRK), Amazon.com, Inc. (NASDAQ:AMZN), Covetrus (NASDAQ:CVET), Chewy (NYSE:CHWY), Abivax (OTCMKTS:AAVXF), Organicell Regenerative Medicine, Inc. (OTCMKTS:BPSR), Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), Fate Therapeutics, Inc. (NASDAQ:FATE), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Applied Genetic Technologies Corporation (NASDAQ:AGTC), Epizyme, Inc. (NASDAQ:EPZM), Blueprint Medicines Corp. (NASDAQ:BPMC), Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), Novartis AG (NYSE:NVS), Beam Therapeutics (NASDAQ:BEAM), Generation Bio Co. (NASDAQ:GBIO), SpringWorks Therapeutics (NASDAQ:SWTX), Argenx SE (ADR) (NASDAQ:ARGX), Gilead Sciences, Inc. (NASDAQ:GILD), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Immunomedics, Inc. (NASDAQ:IMMU), aTyr Pharma (NASDAQ:LIFE), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), NeuBase Therapeutics, Inc. (NASDAQ:NBSE), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Wave Life Sciences Ltd (NASDAQ:WVE), Catabasis Pharmaceuticals Inc (NASDAQ:CATB), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), AbbVie Inc. (NYSE:ABBV), Bristol-Myers Squibb Company (NYSE:BMY), Seelos Therapeutics, Inc. (NASDAQ:SEEL), Kazia Therapeutics Limited (NASDAQ:KZIA), Akebia Therapeutics, Inc. (NASDAQ:AKBA), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), 22nd Century Group, Inc. (NYSEAMERICAN:XXII), EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG), Boomer Holdings, Inc. (OTCMKTS:BOMH)

Medical Devices

June 12, 2020

Buy ($175)

Companies covered: Medtronic, Inc. (NYSE:MDT), Intuitive Surgical, Inc. (NASDAQ:ISRG), Edwards Lifesciences Corporation (NYSE:EW), DexCom, Inc. (NASDAQ:DXCM), Abbott Laboratories (NYSE:ABT), Boston Scientific Corporation (NYSE:BSX), ViewRay Inc. (NASDAQ:VRAY), ResMed Inc. (NYSE:RMD), Shockwave Medical (NASDAQ:SWAV), Inspire Medical Systems (NYSE:INSP), Becton, Dickinson and Company (NYSE:BDX), Hologic, Inc. (NASDAQ:HOLX), Globus Medical, Inc. (NYSE:GMED), Tactile Systems Technology, Inc. (NASDAQ:TCMD), AxoGen, Inc. (NASDAQ:AXGN), NeuroMetrix, Inc. (NASDAQ:NURO), Bio-Techne Corp (NASDAQ:TECH), Stereotaxis, Inc. (NASDAQ:STXS), Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Motus GI Holdings, Inc. (NASDAQ:MOTS)